nasdaq:srne
|
566198
|
Mar 23rd, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
185.00
|
Open
|
|
Mar 23rd, 2024 12:35AM
|
Mar 23rd, 2024 07:26PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 22nd, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
185.00
|
Open
|
|
Mar 22nd, 2024 12:08AM
|
Mar 22nd, 2024 07:14PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 21st, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
185.00
|
Open
|
|
Mar 21st, 2024 05:58PM
|
Mar 21st, 2024 05:58PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 20th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
185.00
|
Open
|
|
Mar 20th, 2024 01:01AM
|
Mar 20th, 2024 07:59PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 19th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
185.00
|
Open
|
|
Mar 18th, 2024 11:56PM
|
Mar 19th, 2024 06:31PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 18th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
186.00
|
Open
|
|
Mar 18th, 2024 12:33AM
|
Mar 18th, 2024 07:44PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 16th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
186.00
|
Open
|
|
Mar 15th, 2024 11:47PM
|
Mar 16th, 2024 07:30PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 15th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
186.00
|
Open
|
|
Mar 15th, 2024 07:26AM
|
Mar 15th, 2024 09:21AM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 14th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
186.00
|
Open
|
|
Mar 13th, 2024 11:46PM
|
Mar 14th, 2024 12:43PM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|
nasdaq:srne
|
566198
|
Mar 13th, 2024 12:00AM
|
Sorrento Therapeutics, Inc.
|
15K
|
191.00
|
Open
|
|
Mar 12th, 2024 11:40PM
|
Mar 13th, 2024 11:13AM
|
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
|
Open
|
Biopharma, cancer, COVID-19, Diagnostics, infectious diseases, and Non-opioid pain management
|
Open
|
4955 Directors Place
|
San Diego
|
California
|
US
|
92121
|
|
Sorrento Therapeutics
|
|
Health Care Equipment & Services
|